General Information of Drug (ID: DMNOZAI)

Drug Name
ALX-0646 Drug Info
Synonyms
ALC-2527XX; ALC-900XX; ALC-901XX; ALC-902XX; ALC-905XX; ALC-907XX; ALC-913; ALC-918; ALC-918XX; ALC-947XX; ALC-948XX; ALC-962XX; ALC-963XX; ALC-973XX; ALC-974XX; ALX-2324; ALX-2325; ALX-2326; ALX-2354XX; ALX-2355XX; ALX-2356XX; ALX-2357XX; ALX-2436XX; ALX-2437XX; ALX-2458XX; ALX-2459XX; ALX-2476XX; ALX-2477XX; ALX-2503XX; ALX-2504XX; ALX-2581; ALX-2582; ALX-2592; ALX-646CL; ALX-912
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
9860595
CAS Number
CAS 208464-67-9
TTD Drug ID
DMNOZAI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Eletriptan DMW649X Migraine 8A80 Approved [4]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [4]
Frovatriptan DM7RE8P Migraine 8A80 Approved [4]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [5]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [6]
Almogran DM7I64Z Migraine 8A80 Approved [7]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [8]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [9]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008400)
2 Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
3 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
6 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
7 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
8 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Company report (NeurAxon)